Cryolife Inc  

(Public, NYSE:CRY)   Watch this stock  
Find more results for ASHLEY M. CAPPS�
10.12
Nov 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 8.40 - 12.14
Open     -
Vol / Avg. 0.00/106,336.00
Mkt cap 282.77M
P/E 20.08
Div/yield 0.03/1.19
EPS 0.50
Shares 27.94M
Beta 1.08
Inst. own 60%
Feb 18, 2015
Q4 2014 CryoLife Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 3, 2014
CryoLife Inc at Piper Jaffray Healthcare Conference - 1:30PM EST - Add to calendar
Nov 20, 2014
CryoLife, Inc. at Canaccord Genuity Medical Technologies & Diagnostics Forum - Webcast
Oct 28, 2014
Q3 2014 CryoLife Inc Earnings Call - Webcast
Oct 28, 2014
Q3 2014 CryoLife Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 6.27% 11.49%
Operating margin 8.13% 7.52%
EBITD margin - 13.97%
Return on average assets 5.35% 9.75%
Return on average equity 6.23% 11.58%
Employees 510 -
CDP Score - -

Address

STE 142, 1655 ROBERTS BOULEVARD N W
KENNESAW, GA 30144
United States - Map
+1-770-4193355 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CryoLife, Inc. (CryoLife,) is a biological medical device company. The Company preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The Company operates in two segments: preservation services and medical devices segment. The preservation services segment includes services revenues from the preservation of cardiac and vascular tissues during the year ended December 31, 2011. The medical devices segment includes revenues from product sales of BioGlue, BioFoam, PerClot, HemoStase and revascularization technologies, as well as sales of other medical devices.In August 2014, the Company acquired distribution rights to PhotoFix, a bovine pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde from Genesee BioMedical, Inc., a Denver, Colorado-based manufacturer of cardiac surgery instruments and devices.

Officers and directors

Steven G. Anderson Executive Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James Patrick Mackin President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
D. Ashley Lee CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
David P. Lang Senior Vice President - International Sales and Marketing
Age: 67
Bio & Compensation  - Reuters
Bruce G. Anderson Vice President - U.S. Sales and Marketing
Age: 47
Bio & Compensation  - Reuters
Scott B. Capps Vice President - Clinical Research
Age: 47
Bio & Compensation  - Reuters
David M. Fronk Vice President - Regulatory Affairs and Quality Assurance
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David C. Gale Ph.D. Vice President - Research & Development
Age: 46
Bio & Compensation  - Reuters
Jon W. Salveson Director
Age: 49
Bio & Compensation  - Reuters
Thomas F. Ackerman Independent Director
Age: 59
Bio & Compensation  - Reuters